Ferroptosis

Overview

For much of cell biology's history, two forms of regulated cell death — apoptosis and later necroptosis — dominated thinking. In 2012, Brent Stockwell and colleagues defined a distinct iron-dependent cell death program that they named ferroptosis, triggered in cancer cells by the small molecule erastin. Since then, ferroptosis has emerged as a physiologically and therapeutically important pathway, distinct in morphology, genetics, and biochemistry from apoptosis, pyroptosis, and necroptosis.

Ferroptotic cells show small, dense mitochondria with reduced cristae and ruptured outer membranes but generally lack the chromatin condensation and caspase activation that define apoptosis. At the molecular level, ferroptosis arises when redox-active iron catalyzes uncontrolled peroxidation of polyunsaturated fatty acid (PUFA) phospholipids in membranes, and the cell's defenses — particularly glutathione peroxidase 4 (GPX4) — cannot keep up.

How It Works

Two Sides of a Balance

Ferroptosis is governed by the balance between lipid peroxide generation and repair:

Drivers

• Intracellular labile iron (Fe2+), accessed from ferritin stores through ferritinophagy (a specialized form of autophagy) or acquired via transferrin-TfR1 uptake.
• PUFA-containing phospholipids (especially phosphatidylethanolamines with arachidonic or adrenic acid) generated by ACSL4 and LPCAT3.
• Enzymatic (lipoxygenases, POR) and non-enzymatic (Fenton chemistry) lipid peroxidation.

Defenses

• GPX4, a selenoprotein that uses glutathione (GSH) to reduce lipid hydroperoxides to harmless lipid alcohols.
• System Xc- (SLC7A11/SLC3A2), which imports cystine in exchange for glutamate to generate cysteine for glutathione synthesis.
• FSP1 (AIFM2)-CoQ10 axis, a GPX4-independent lipid radical trap.
• GCH1-BH4 axis, another parallel antioxidant system.
• Nrf2 pathway activation, which induces many antioxidant genes including SLC7A11, glutathione synthesis enzymes, and ferroportin.

Inhibiting cystine import (erastin) depletes cysteine and therefore GSH; inhibiting GPX4 directly (RSL3, ML162) disables the repair arm; iron chelators (deferoxamine) prevent Fe2+ from catalyzing peroxidation. Each of these is widely used in ferroptosis research.

Crosstalk With Other Death and Stress Pathways

Ferroptosis interacts with:

• Autophagy: ferritinophagy (mediated by NCOA4) increases labile iron.
• p53: by repressing SLC7A11, p53 sensitizes cells to ferroptosis.
• Hippo/YAP: TAZ can promote ferroptosis via ANGPTL4-NOX2.
• Mitochondrial function: mitochondria are a major source of lipid ROS and of CoQ10.
• Inflammation: ferroptotic cells release DAMPs (HMGB1) that drive sterile inflammation overlapping with NF-κB responses.

Biological Roles

Physiology

Ferroptosis contributes to the elimination of erythroid precursors in certain conditions, T cell homeostasis, and turnover in developing tissues, though its physiological scope is still being mapped.

Disease

Ferroptosis has been implicated in:

• Neurodegeneration — iron accumulates in Parkinson's, Alzheimer's, and Huntington's brain regions; ferroptosis may contribute to neuronal loss.
• Stroke, traumatic brain injury, and cardiac ischemia-reperfusion — where iron-catalyzed lipid peroxidation drives tissue damage.
• Acute kidney injury — tubular cells appear especially vulnerable.
• Hemochromatosis and hemolysis — iron overload conditions.
• Cancer — many tumor cells are highly dependent on glutathione and GPX4, making ferroptosis induction a promising therapeutic strategy, especially in mesenchymal and therapy-resistant states.

Relevance to Peptides

• Peptide-based ferroptosis inducers: peptides that deliver drugs selectively to iron-rich tumor cells, or that inhibit SLC7A11/GPX4 through PROTAC-like architectures, are an emerging area.
• Cell-penetrating peptides carrying GPX4 inhibitors or ferroptosis sensitizers exploit the pathway's strong dependence on a small number of druggable choke points.
• Antimicrobial peptides and host defense: LL-37 and others can modulate cellular iron handling and lipid peroxidation, intersecting with ferroptosis in infection and inflammation.
• Peptide ferroptosis biosensors are used in research to track lipid peroxidation in real time.

Therapeutic Implications

The therapeutic strategy depends on context:

• Inducing ferroptosis is attractive in cancers that resist apoptosis, particularly those with mesenchymal or drug-tolerant phenotypes. Candidates include GPX4 inhibitors, SLC7A11 inhibitors, and combination regimens with immunotherapy (CD8 T cells promote tumor ferroptosis via interferon-γ).
• Inhibiting ferroptosis is the goal in acute tissue injury, neurodegeneration, and iron overload. Liproxstatin, ferrostatin, vitamin E-like radical trapping antioxidants, and iron chelators are in development.

Current Questions

How ferroptosis executes its final membrane rupture, how to achieve tumor-selective ferroptosis without damaging sensitive tissues like the brain or kidney, and how the pathway interacts with mitochondrial function, autophagy, and immunity remain active lines of research. Ferroptosis's strong immunogenicity — distinct from the generally tolerogenic nature of apoptosis — is also reshaping thinking about immunogenic cell death in oncology.